Lixisenatide | CAS:827033-10-3

We serve Lixisenatide CAS:827033-10-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Lixisenatide

Chemical Name:Lixisenatide
CAS.NO:827033-10-3
Synonyms:Lixisenatide
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Lixisenatide is used as a diet and exercise supplement to treat type II diabetes.



Contact us for information like Lixisenatide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Lixisenatide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Lixisenatide Use and application,Lixisenatide technical grade,usp/ep/jp grade.


Related News: At the same time, through years of imitation and advanced technology learning, more and more domestic companies have participated in the field of highly original and characteristic APIs.Hexamethylcyclotrisiloxane manufacturer Christopher Coleman, assistant professor of infection immunology at Nottingham University, told Sky News: “They get their name because under the electron microscope there’s a bright ring around the central core of the virus, like the sun essentially.”2-Naphthaleneboronic acid supplier Christopher Coleman, assistant professor of infection immunology at Nottingham University, told Sky News: “They get their name because under the electron microscope there’s a bright ring around the central core of the virus, like the sun essentially.”3',5'-cyclic AMP vendor International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.